The rating scale preference measure as an evaluative measure in systemic lupus erythematosus

Abstract

Preference measures may be useful tools to assess patients' overall health-related quality of life. We studied the validity and sensitivity to change of the rating scale preference measure in patients with systemic lupus erythematosus (SLE), and compared its properties with those of the patient global assessment of SLE activity, in a prospective longitudinal observational study of changes in the symptoms and clinical disease activity of 23 patients. Patients were assessed every two weeks for up to 40 weeks. Construct validity was assessed by the strength of correlations between changes over time in the rating scale preference measure and patient global assessment and changes in the physician global assessment, Systemic Lupus Activity Measure (SLAM), European Consensus Lupus Activity Measure (ECLAM), the British Isles Lupus Assessment Group index (BILAG), and Systemic Lupus Erythematosus Disease Activity Index (SLEDAI). Changes in the rating scale were more highly correlated with changes in each of these standards than were changes in the patient global assessment, demonstrating the construct validity of this measure. Sensitivity to change was measured using the two-week interval of greatest change in either the physician global assessment or the SLE activity measures as standards. The rating scale preference measure was less sensitive to change than the patient global assessment when tested against four different standards. The sensitivity to change of the rating scale was less than one-half that of the patient global assessment when either the SLAM or ECLAM was used as the standard. Although these results support the validity of the rating scale as a measure of health-related quality of life in patients with SLE, its limited sensitivity to change may make it less attractive as an endpoint measure in clinical trials.

Keywords

preference measures rating scale patient assessment sensitivity to change systemic lupus erythematosus

Get full access to this article

View all access options for this article.

References

Guyatt GH , Feeny DH , Patrick DL . Measuring health-related quality of life . Ann Intern Med 1993; 118: 622–629 .

Torrance GW . Measurement of health state utilities for economic appraisal. A review . J Health Econ 1986; 5: 1–30 .

Bombardier C , Ware J , Russell IJ et al. Auranofin therapy and quality of life in patients with rheumatoid arthritis. Results of a multicenter trial . Am J Med 1986; 81: 565–578 .

Canadian Erythropoietin Study Group . Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis . Br Med J 1990; 300: 573–578 .

Katz JN , Phillips CB , Fossel AH , Liang MH . Stability and responsiveness of utility measures . Med Care 1994; 32: 183–188 .

Jenkinson C , Gray A , Doll H et al. Evaluation of index and profile measures of health status in a randomized controlled trial. Comparison of the Medical Outcomes Study 36-item short form health survey, EuroQol, and disease specific measures . Med Care 1997; 35: 1109 –1118 .

Patrick DL , Deyo RA . Generic and disease-specific measures in assessing health status and quality of life . Med Care 1989; 27(Suppl): S217–S232 .

Murawski MM , Miederhoff PA . On the generalizability of statistical expressions of health related quality of life instrument responsiveness: a data synthesis . Qual Life Res 1998; 7: 11–22 .

Moore AD , Clarke AE , Danoff DS et al. Can health utility measures be used in lupus research? A comparative validation and reliability study of 4 utility indices . J Rheumatol 1999; 26: 1285–1290 .

10.

Ward MM , Marx AS , Barry NN . Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus . J Rheumatol 2000; 27: 664–670 .

11.

Bakker C , Rutten M , van Doorslaer E et al. Feasibility of utility assessment by rating scale and standard gamble in patients with ankylosing spondylitis or fibromyalgia . J Rheumatol 1994; 21: 269–274 .

12.

Liang MH , Socher SA , Larson MG , Schur PH . Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus . Arthritis Rheum 1989; 32: 1107–1118 .

13.

Vitali C , Bencivelli VW , Isenberg DA et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score . Clin Exp Rheum 1992; 10: 541–547 .

14.

Symmons DPM , Coppock JS , Bacon PA et al. Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus . QJM 1988; 69: 927–937 .

15.

Stoll T , Stucki G , Malik J et al. Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus . Ann Rheum Dis 1996; 55: 756–760 .

16.

Bombardier C , Gladman DD , Urowitz MB et al. Derivation of the SLEDAI. A disease activity index for lupus patients . Arthritis Rheum 1992; 35: 630–640 .

17.

Bencivelli VW , Vitali C , Isenberg DA et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Development of a computerized clinical chart and its application to the comparison of different indices of disease activity . Clin Exp Rheumatol 1992; 10: 549–554 .

18.

Fortin PR , Abrahamowicz M , Danoff D . Small changes in outpatient lupus activity are better detected by clinical instruments than by laboratory tests . J Rheumatol 1995; 22: 2078–2083 .

19.

Liang MH , Fossel AH , Larson MG . Comparisons of five health status instruments for orthopedic evaluation . Med Care 1990; 28: 632–642 .

20.

Hsiao C . Analysis of Panel Data. Cambridge University Press: Cambridge , 1986.

21.

Ward MM , Leigh JP . Pooled time series regression analysis in longitudinal studies . J Clin Epidemiol 1993; 46: 645–659 .

22.

Nelson E , Conger B , Douglass R et al. Functional health status levels of primary care patients . JAMA 1983; 249: 3331 –3338 .

23.

Brody DS , Miller SM , Lerman CE et al. Patient perception of involvement in medical care: relationship to illness attitudes and outcomes . J Gen Intern Med 1989; 4: 506–511 .

24.

Lorig KR , Cox T , Cuevas Y et al. Converging and diverging beliefs about arthritis: Caucasian patients, Spanish speaking patients, and physicians . J Rheumatol 1984; 11: 76–79 .

25.

Kwoh CK , O'Connor GT , Regan-Smith MG et al. Concordance between clinician and patient assessment of physical and mental health status . J Rheumatol 1992; 19: 1031–1037 .

26.

Piersma HL , Boes JL . Agreement between patient self-report and clinician rating: concurrence between the BSI and the GAF among psychiatric inpatients . J Clin Psychol 1995; 51: 153 –157 .

27.

Nerenz DR , Repasky DP , Whitehouse FW , Kahkonen DM . Ongoing assessment of health status in patients with diabetes mellitus . Med Care 1992; 30(Suppl): MS112–MS124 .

28.

Feeny DH , Torrance GW . Incorporating utility-based quality-of-life assessment measures in clinical trials. Two examples . Med Care 1989; 27(Suppl 3): S190–S204 .

29.

Fries JF , Ramey DR . `Arthritis specific' global health analog scales assess `’generic' health related quality-of-life in patients with rheumatoid arthritis . J Rheumatol 1997; 24: 1697 –1702 .

30.

Hurst HP , Jobanputra P , Hunter M et al. Validity of Euroqol —Eth— a generic health status instrument <Eth> in patients with rheumatoid arthritis . Br J Rheumatol 1994; 33: 655–662 .

31.

Bakker C , Rutten M , van Santen-Hoeufft M et al. Patient utilities in fibromyalgia and the association with other outcome measures . J Rheumatol 1995; 22: 1536–1543 .

32.

Bakker C , Rutten-van Mölken M , Hidding A et al. Patient utilities in ankylosing spondylitis and the association with other outcome measures . J Rheumatol 1994; 21: 1298–1304 .